Erasca to Present ERAS-0015 Data in Barcelona

The U.S. biotech will share early pancreatic cancer data at the EORTC-NCI-AACR meeting, as its market value trails Revolution Medicines.

Updated on Nov. 19, 2026 in Cancer

Isometric editorial illustration of a unlabeled molecular cluster of angular solid forms in slate blue with one amber segment isolated at center on a cream field.
Erasca will present early data on its pan-RAS inhibitor ERAS-0015 at the EORTC-NCI-AACR meeting in Barcelona on Friday, as its $5 billion market value trails Revolution Medicines' $35 billion. AI Illustration. Upload story photo >

Erasca will present new data on its pan-RAS inhibitor ERAS-0015 at the EORTC-NCI-AACR meeting in Barcelona on Friday. The company has so far released only scant data from an early-stage study through press releases.

Why it matters

Erasca's market value of $5 billion is a fraction of the $35 billion carried by Revolution Medicines, making the upcoming data a key test of the company's claims. Pan-RAS inhibitors are an active area of cancer drug development, and investors are watching how such candidates perform.

The company has signaled an overall response rate of roughly 40% for ERAS-0015 in second-line-plus pancreatic cancer, based on early-stage data shared through press releases. The complete dataset and trial conditions have not been disclosed, and independent verification awaits the Barcelona presentation.

The players

Erasca

A U.S.-based biotechnology company developing targeted cancer therapies, including the pan-RAS inhibitor ERAS-0015.

Revolution Medicines

A biotechnology company developing RAS-targeted cancer drugs, valued at $35 billion and used here as a comparison to Erasca's market position.

The details

Erasca, a U.S.-based biotech company, will present ERAS-0015 data at the EORTC-NCI-AACR meeting in Barcelona. CEO Jonathan Lim has told investors at investment banking conferences that the response rate would be meaningfully different from that of Rasonque.

Timeline

  1. November 19, 2026: Article published on Erasca's KRAS-targeted treatment.

  2. Friday, November 20, 2026: Erasca presents ERAS-0015 data at the EORTC-NCI-AACR meeting in Barcelona.

Roadmap

ERAS-0015 extends the RAS-targeted drug class beyond earlier mutation-specific KRAS G12C inhibitors toward a pan-RAS approach aimed at a wider range of tumors. Competition in this space is intensifying, and how Erasca's pancreatic cancer data compares with those of larger rivals will shape its position.

For people with pancreatic cancer who have already progressed through earlier lines of treatment, a new drug option would depend on whether trial data holds up in later review. Any eventual availability will require regulatory approval, which is not addressed by the early data.

The takeaway

Early company-released data should be weighed cautiously until full results are presented and reviewed by independent scientists. Readers following pancreatic cancer research can track the Barcelona presentation for the detail that press releases have not yet provided.

What happens next

Erasca is scheduled to present ERAS-0015 data at the EORTC-NCI-AACR meeting in Barcelona on Friday, November 20, 2026.

Further reading

For broader background on how these therapies are being studied, see the Cancer section.

Source note: This article includes information reported by STAT.